Company Profile

APD Life Sciences Inc (AKA: Reproduction Resources~BioPore Inc)
Profile last edited on: 2/5/15      CAGE: 343U8      UEI:

Business Identifier: Accelerating Product Development in the Life Sciences
Year Founded
2003
First Award
1988
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2701 Carolean Industrial Drive Suite 2
State College, PA 16801
   (814) 234-4835
   N/A
   www.apdls.com
Location: Single
Congr. District: 12
County: Centre

Public Profile

APD Life Sciences, formed in 2003 as a successor to BioPore, Inc. - itself an active SBIR Awardee engages business approach that is grounded in development of technology(ies) to the level at which it can be licensed out to others. Initial products dealt with fertility enhancement in human and commodity animals and blood cell storage have been transferred to partners focused on later stage development. Results of two SBIR-supported projects await transfer to such partners. Project 1: A disposable detector component was developed for non-invasive spectroscopic analysis of sealed containers/systems. Potential industry applications include biomanufacturing, food safety, bio-defense and public health. Using fluorescent bio-indicators, this detector is easily integrated into existing systems for assessment of internal pH, oxygen tension and microbial contamination; additional applications under development. Design advantages include: no need to open container to sample contents; capacity for either on-site or robotic interrogation; direct electronic link to data repository; "instant" availability of test results; and fully-loaded cost of 10-15% of competitive methods. A lab-scale prototype and representative data are complete and available for examination. We seek to sublicence manufacturing, marketing and sales for specific fields-of-use [e.g., food safety and spoilage; biomanufacturing], and can work with licensee to optimize additional prototypes and protocols. Project 2: A novel and general approach to enhancing clinical and research analyses was developed, based upon recombinant proteins with ultra-high affinities for serum albumin and other major serum components. Virtually all current clinical analyses, home diagnostic kits, and developing approaches using multiplexing and proteomic readouts are limited by one-or-more of these features: (a) insufficient sample for all needed tests; (b) inappropriate sensitivity; and/or (c) difficulties in standardization across vendors and laboratories. These limits are an unavoidable downside of the most popular approach to assay design; use of antibodies which are limited by the affinity for antigen. The firm's approach is to retain the advantages of the current methods while addressing virtually all of its problems. Five products, based upon affinities for albumin or IgG were developed using a silica-bead-based, spin-tube format and are in sales. Additional binding proteins relevant to other important serum components are in development. When successfully implemented, an enhanced method for assessing both new clinical paradigms [such as use of biotherapeutics] as well as improving more traditional diagnostic techniques will be attained.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $97,535
Project Title: High Throughput Screening Of Bacterial Collections For Surface Proteins Of Commer
2006 1 NIH $124,736
Project Title: Low-Cost Affinity System for Preparation of Plasma/Serum for Biomarker Analysis
2004 2 NIH $1,086,817
Project Title: Non-Invasive Detection Of Bacteria In Blood Products
2002 2 NIH $850,000
Project Title: UPSEBP, A Profertility Protein in Human Semen
2002 2 NIH $850,519
Project Title: Processing Cryopreserved Human Sperm

Key People / Management

  Roy H Hammerstedt -- President

  Rupert P Amann -- Vice President

  Edward G Buss

  Mark DuMars -- Business Advisor

  Surinder P S Gill

  Allen T Phillips

  Stephen S Schwartz -- Scientist

Company News

There are no news available.